Monte Rosa Therapeutics Inc (NASDAQ: GLUE) has experienced a decline in its stock price by -17.85 compared to its previous closing price of 7.06. However, the company has seen a fall of -7.50% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-20 that Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE ) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Andrew Funderburk – Senior Vice President, Investor Relations and Strategic Finance Markus Warmuth – Chief Executive Officer Filip Janku – Chief Medical Officer Sharon Townson – Chief Scientific Officer Phil Nickson – Chief Business and Legal Officer Conference Call Participants Kelly Shi – Jefferies Edward Tenthoff – Piper Sandler Mark Fromm – TD Cowen Robert Driscoll – Wedbush Michael Schmidt – Guggenheim Eric Joseph – JPMorgan Operator Greetings, and welcome to Monte Rosa Therapeutics Conference Call to discuss the company’s pipeline updates and clinical results. At this time, all participants are in a listen-only mode.
Is It Worth Investing in Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Right Now?
GLUE has 36-month beta value of 1.29. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for GLUE is 45.95M, and currently, short sellers hold a 17.50% ratio of that float. The average trading volume of GLUE on March 24, 2025 was 722.49K shares.
GLUE’s Market Performance
The stock of Monte Rosa Therapeutics Inc (GLUE) has seen a -7.50% decrease in the past week, with a -12.52% drop in the past month, and a -24.38% fall in the past quarter. The volatility ratio for the week is 14.19%, and the volatility levels for the past 30 days are at 10.32% for GLUE. The simple moving average for the past 20 days is -5.47% for GLUE’s stock, with a -4.02% simple moving average for the past 200 days.
Analysts’ Opinion of GLUE
Many brokerage firms have already submitted their reports for GLUE stocks, with Wells Fargo repeating the rating for GLUE by listing it as a “Equal Weight.” The predicted price for GLUE in the upcoming period, according to Wells Fargo is $11 based on the research report published on December 19, 2024 of the previous year 2024.
Wedbush, on the other hand, stated in their research note that they expect to see GLUE reach a price target of $11. The rating they have provided for GLUE stocks is “Outperform” according to the report published on February 15th, 2024.
Wells Fargo gave a rating of “Overweight” to GLUE, setting the target price at $18 in the report published on January 03rd of the previous year.
GLUE Trading at -5.91% from the 50-Day Moving Average
After a stumble in the market that brought GLUE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.23% of loss for the given period.
Volatility was left at 10.32%, however, over the last 30 days, the volatility rate increased by 14.19%, as shares sank -6.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.11% lower at present.
During the last 5 trading sessions, GLUE fell by -7.50%, which changed the moving average for the period of 200-days by +45.73% in comparison to the 20-day moving average, which settled at $6.14. In addition, Monte Rosa Therapeutics Inc saw -16.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GLUE starting from Versant Venture Capital VI, L., who sale 89,990 shares at the price of $9.66 back on Oct 28 ’24. After this action, Versant Venture Capital VI, L. now owns 2,007,948 shares of Monte Rosa Therapeutics Inc, valued at $869,240 using the latest closing price.
Versant Venture Capital VI, L., the 10% Owner of Monte Rosa Therapeutics Inc, sale 67,905 shares at $9.16 during a trade that took place back on Oct 29 ’24, which means that Versant Venture Capital VI, L. is holding 1,573,453 shares at $621,801 based on the most recent closing price.
Stock Fundamentals for GLUE
Current profitability levels for the company are sitting at:
- -1.07 for the present operating margin
- 0.95 for the gross margin
The net margin for Monte Rosa Therapeutics Inc stands at -0.96. The total capital return value is set at -0.29. Equity return is now at value -36.15, with -19.58 for asset returns.
Based on Monte Rosa Therapeutics Inc (GLUE), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at 0.98.
Currently, EBITDA for the company is -81.11 million with net debt to EBITDA at 2.49. When we switch over and look at the enterprise to sales, we see a ratio of 2.31. The receivables turnover for the company is 437.12for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.40.
Conclusion
To put it simply, Monte Rosa Therapeutics Inc (GLUE) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
